byiShook Opinion
Mar 19, 2025 - 13:15
Immunovant and Roivant Sciences said Wednesday their rare disease drug succeeded in a final-phase study, but the duo won't seek approval. The post Roivant And Immunovant Won't Seek Approval Despite Phase 3 Win. Why Shares Rallied. appeared first on Investor's Business Daily.
Immunovant and Roivant Sciences said Wednesday their rare disease drug succeeded in a final-phase study, but the duo won't seek approval.
The post Roivant And Immunovant Won't Seek Approval Despite Phase 3 Win. Why Shares Rallied. appeared first on Investor's Business Daily.